Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Rendu Bio is a leading Chinese biotechnology company specializing in molecular diagnostics, particularly focusing on RNA-based detection technologies. The company has developed a proprietary platform known as Simultaneous Amplification and Testing (SAT), which allows for the rapid and sensitive detection of pathogens by targeting ribosomal RNA. Their commercial portfolio includes a wide range of diagnostic kits for sexually transmitted infections, respiratory diseases, and reproductive health. Rendu Bio is recognized for its innovation in automated molecular testing systems that integrate sample processing and detection, providing efficient solutions for clinical laboratories and hospitals.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Ren De.